论文部分内容阅读
血管紧张素转换酶抑制剂治疗充血性心力衰竭已广泛应用于临床,有充分资料认为心功能夏Ⅲ～Ⅳ级病人,用此药可使病人血液动力学持续性改善,增加运动耐力。然而,在初始治疗时,应注意仔细估价病人临床及生化情况。用转换酶抑制剂治疗的心力衰竭病人15％可产生首剂低血压,虽一般不影响肾功能,但长期应用时,偶而可出现肾功能障碍。为了预防和及早发现这些副作用,给予妥善处理、制定某些原则是必要的,但这些原则不适用于高血压病的降血压治疗。
Angiotensin-converting enzyme inhibitors for the treatment of congestive heart failure has been widely used in clinical, there is sufficient data that the summer of patients with grade Ⅲ ~ Ⅳ patients, this drug can make the patient continued to improve hemodynamics, increased exercise tolerance. However, careful consideration should be given to the clinical and biochemical status of the patient during initial treatment. 15% of patients with heart failure treated with a translational enzyme inhibitor can produce the first dose of hypotension, although generally does not affect renal function, but occasionally there may be renal dysfunction in long-term use. In order to prevent and early detection of these side effects, to give proper treatment, the development of certain principles are necessary, but these principles do not apply to the treatment of hypertension in the treatment of hypertension.